In short
A groundbreaking clinical trial is underway to evaluate the potential of REGN7257, an experimental drug designed to treat severe aplastic anemia (SAA). This study focuses on patients whose condition has not responded well to previous immunosuppressive therapies. The trial aims to assess the safety, tolerability, and effectiveness of REGN7257 in improving blood cell production and reducing the need for transfusions in SAA patients.
At a glance
- Drug Name
- REGN7257
- Condition Studied
- Severe Aplastic Anemia (SAA)
- Study Design
- Phase 1/2, two-part study (Part A and Part B)
- Administration Method
- Intravenous (IV) infusion
- Primary Outcomes
- Incidence of adverse events, serious adverse events, treatment-emergent adverse events, and overall response rate
- Secondary Outcomes
- Time to response, transfusion requirements, changes in blood cell counts, immune cell subsets, drug concentrations, and anti-drug antibody formation
- Study Duration
- Approximately 78 weeks
What is REGN7257?
REGN7257 is an experimental drug that is currently being researched for the treatment of severe aplastic anemia (SAA). It is classified as an anti-interleukin 2 receptor subunit gamma (IL2RG) monoclonal antibody. This means it's a type of protein designed to target and block a specific part of the immune system that may be involved in the development of SAA.
Target Condition: Severe Aplastic Anemia (SAA)
Severe aplastic anemia (SAA) is a serious bone marrow disorder. In this condition, the bone marrow fails to produce enough blood cells, including red blood cells, white blood cells, and platelets. This leads to various health problems such as fatigue, increased risk of infections, and bleeding issues.
Purpose of the Clinical Study
The main goal of this study is to investigate REGN7257 in patients with SAA who have not responded well to other immunosuppressive therapies (ISTs) or have experienced a relapse. The research aims to answer several important questions:
- How safe and tolerable is REGN7257 for patients with SAA?
- What side effects might patients experience when taking REGN7257?
- How does REGN7257 work in the body?
- How much REGN7257 remains in the blood after dosing?
- Can REGN7257 increase certain blood cell counts after treatment?
- How quickly does REGN7257 work to raise blood cell counts?
- In patients who respond positively, how long does the response last throughout the study?
- Can REGN7257 reduce the need for platelet and red blood cell transfusions?
- How does REGN7257 affect immune cell counts and composition?
- Does the body produce antibodies against REGN7257 (anti-drug antibodies)?
Study Design and Administration
The clinical trial for REGN7257 is designed in two parts:
- Part A: This involves single ascending dose (SAD) escalation cohorts. This means that different groups of patients will receive a single dose of REGN7257, with each group receiving a higher dose than the previous one.
- Part B: This part involves multiple REGN7257 dosages, likely to assess the effects of repeated treatments.
In both parts of the study, REGN7257 is administered through intravenous (IV) infusion. This means the drug is given directly into the patient's vein.
Primary Outcomes Being Measured
The study will primarily focus on the safety and effectiveness of REGN7257. Key measurements include:
- Adverse events (AEs) and serious adverse events (SAEs): These are any undesirable experiences associated with the use of REGN7257. They will be monitored for 12 months post-treatment (approximately 52 weeks) and through the end of the study (approximately 78 weeks).
- Treatment-emergent adverse events (TEAEs): These are adverse events that appear or worsen after starting the treatment. They will be monitored for their incidence and severity.
- Overall response rate (ORR): This measures how many patients show improvement in their condition after 6 months (approximately 26 weeks) of treatment.
Secondary Outcomes Being Evaluated
The study will also look at several secondary outcomes to further understand the effects of REGN7257:
- Complete response (CR) and partial response (PR): These measure the degree of improvement in the patient's condition after 3 months (approximately 12 weeks) of treatment.
- Time to best response and time to first response: These measure how quickly patients show improvement.
- Any clinical response: This will be monitored until the end of the study (approximately 52 or 78 weeks).
- Transfusion needs: The study will track how many platelet and red blood cell transfusions patients need over time.
- Blood cell counts: Changes in various blood cell counts (lymphocytes, neutrophils, hemoglobin, reticulocytes, and platelets) will be monitored.
- Immune cell subsets: Changes in T cells, B cells, and Natural Killer (NK) cells will be observed.
- Drug concentration: The amount of REGN7257 in the blood over time will be measured.
- Anti-drug antibodies (ADA): The study will check if patients develop antibodies against REGN7257 over time.